top of page
Gradient Layer.png

ROADS Clinical Study

for patients with newly

diagnosed metastatic

brain tumors

Have you or someone you know

been newly diagnosed with a

metastatic brain tumor?

If so, you should be aware of the opportunity to participate in

the ROADS Clinical Study.

This important clinical study compares 2 FDA-cleared radiation

treatments that are proven safe and effective: GammaTile®

Surgically Targeted Radiation Therapy (STaRT) and stereotactic

radiotherapy (SRT).

The ROADS Clinical Study is enrolling now at participating

hospitals across the country.

Do you quality for the study?

Have been newly diagnosed with 1 or more operable metastatic brain tumors

Are aged 18 years or older

Are not pregnant or planning a pregnancy

Live near a participating hospital VIEW PARTICIPATING SITES

Have not yet scheduled surgery, or surgery is scheduled for a week or more from today

For more information contact a participating hospital or take the ROADS Patient Evaluation.

video background.png

Learn more about the ROADS Clinical Study

< Watch the video


Metastatic brain tumors (also called secondary brain tumors) are caused by cancer cells that have metastasized or spread to the brain from a different part of the body.


Radiation therapy kills cancer cells and shrinks tumors. It is often combined with surgery and

chemotherapy to help eliminate any remaining tumor cells and prevent the tumor from returning.[1-3]

The ROADS Clinical Study will provide more information about how effective GammaTile Therapy and SRT are at preventing brain tumor recurrence.


Study participants will be randomly divided into 2 treatment groups:

   Brain tumor removal surgery + SRT LEARN MORE >

   Brain tumor removal surgery + GammaTile Therapy LEARN MORE >


Following brain tumor removal surgery, clinical study participants will receive either GammaTile Therapy

or SRT to the area where the tumor was.


Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.


  1. RT Answers Web site. Accessed February 6, 2022.

  2. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.

  3. GammaTile Therapy Instructions for Use. Tempe, AZ. GT Medical Technologies; 2020.

bottom of page